• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

    2/10/22 8:44:54 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRE alert in real time by email
    SC 13G/A 1 d258346dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. 2)

     

     

    Aprea Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    03836J102

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐    Rule 13d-1(b)

    ☒    Rule 13d-1(c)

    ☐    Rule 13d-1(d)

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures V, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13G is filed by Versant Venture Capital V, L.P. (“VVC V”), Versant Affiliates Fund V, L.P. (“VAF V”), Versant Ophthalmic Affiliates Fund I, L.P. (“VOA”), Versant Ventures V, LLC (“VV V”), Versant Ventures V (Canada), L.P. (“VV CAN GP”), Versant Venture Capital V (Canada) LP (“VVC CAN”),Versant Ventures V GP-GP (Canada), Inc. (“VV CAN GP-GP”, and together with VVC V, VAF V, VOA, VV V, VV CAN, VVC CAN and VV CAN GP, the “Reporting Persons”). VV V is the sole general partner of each of VVC V, VAF V and VOA and VV CAN GP-GP is the sole general partner of VV CAN GP which is the sole general partner of VVC CAN. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures V GP-GP (Canada), Inc.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures V (Canada), L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Venture Capital V (Canada) LP

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Ontario, Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Affiliates Fund V, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Ophthalmic Affiliates Fund I, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP No. 03836J102   13G   

     

      1.    

      Name of Reporting Persons

     

      Versant Venture Capital V, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

          0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.


    Introductory Note: This Amendment No. 2 (this “Amendment”) amends and supplements the Schedule 13G originally filed by the Reporting Persons with the United States Securities and Exchange Commission (the “Commission”) on October 17, 2019, as amended by Amendment No. 1 filed with the Commission on February 16, 2021 (collectively, the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 2(a)

    Name of Persons Filing

     

      (a)

    Name of Person(s) Filing:

    Versant Vantage I, L.P., Versant Vantage I GP, L.P. and Versant Vantage I GP-GP, LLC, each a reporting person on the Original Schedule 13G, reported the disposition of all of their holdings and beneficial ownership in the Original Schedule 13G, and accordingly, are no longer Reporting Persons.

     

    Item 4

    Ownership

    The following information with respect to the ownership of the Issuer’s Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of the date of the filing of this Amendment:

     

      (a)

    Amount beneficially owned:

    See line 9 of each cover sheet.

     

      (b)

    Percent of class:

    See line 11 of each cover sheet.

     

      (c)

    Number of shares as to which the person has:

     

      i.

    Sole power to vote or to direct the vote: see line 5 of cover sheets.*

     

      ii.

    Shared power to vote or to direct the vote: see line 6 of cover sheets.*

     

      iii.

    Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.*

     

      iv.

    Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.*

     

    *

    Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record and to the extent of its pecuniary interest therein.

     

    Item 5

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☒


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 11, 2022

     

    Versant Ventures V, LLC
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Managing Director
    Versant Ventures V GP-GP (Canada), Inc.
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Director
    Versant Ventures V (Canada), L.P.
    By: Versant Ventures V GP-GP (Canada), Inc.
    Its: General Partner
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Director
    Versant Venture Capital V (Canada) LP
    By: Versant Ventures V (Canada), L.P.
    Its: General Partner
    By: Versant Ventures V GP-GP (Canada), Inc.
    Its: General Partner
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Director
    Versant Affiliates Fund V, L.P.
    By: Versant Ventures V, LLC
    Its: General Partner
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Managing Director
    Versant Ophthalmic Affiliates Fund I, L.P.
    By: Versant Ventures V, LLC
    Its: General Partner
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Managing Director
    Versant Venture Capital V, L.P.
    By: Versant Ventures V, LLC
    Its: General Partner
    By:  

    /s/ Robin L. Praeger

      Robin L. Praeger, Managing Director
    Get the next $APRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APRE

    DatePrice TargetRatingAnalyst
    8/20/2021Neutral → Underweight
    JP Morgan
    8/16/2021Buy → Hold
    Berenberg
    8/16/2021$6.00 → $4.00Neutral
    HC Wainwright & Co.
    8/13/2021$6.00 → $5.00Sector Perform
    RBC Capital
    8/13/2021$5.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $APRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duey Marc bought $25,000 worth of shares (21,459 units at $1.17), increasing direct ownership by 9% to 256,155 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    12/11/25 8:31:55 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren was granted 20,175 shares, increasing direct ownership by 5% to 393,895 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    3/16/26 6:07:28 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. was granted 10,095 shares, increasing direct ownership by 30% to 43,528 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    3/16/26 6:06:04 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical developmentCapital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targe

    3/16/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

    Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific v

    2/18/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

    DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, to take place February 25-26, 2026, virtually. Presentation Details Date/ time:February 26, 2026 8:40 am ESTLocation:      VirtualWebcast link:   click here   The webcast will be available for 90 days at the link above or on the Investors page of the Aprea c

    2/17/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    SEC Filings

    View All

    SEC Form EFFECT filed by Aprea Therapeutics Inc.

    EFFECT - Aprea Therapeutics, Inc. (0001781983) (Filer)

    3/20/26 12:15:06 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Aprea Therapeutics Inc.

    424B3 - Aprea Therapeutics, Inc. (0001781983) (Filer)

    3/19/26 5:16:20 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Aprea Therapeutics Inc.

    S-3/A - Aprea Therapeutics, Inc. (0001781983) (Filer)

    3/17/26 4:30:28 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aprea Therapeutics downgraded by JP Morgan

    JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight

    8/20/21 5:10:20 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics downgraded by Berenberg

    Berenberg downgraded Aprea Therapeutics from Buy to Hold

    8/16/21 7:29:48 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Aprea Therapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously

    8/16/21 6:35:21 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Leadership Updates

    Live Leadership Updates

    View All

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical developmentCapital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targe

    3/16/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Appoints Michael Grissinger to the Board of Directors

    --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

    4/17/25 7:00:00 AM ET
    $ACET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    10/10/24 4:07:13 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    2/14/24 8:00:11 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

    SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

    2/7/24 6:55:18 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Financials

    Live finance-specific insights

    View All

    Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

    BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o

    8/11/22 4:15:00 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update:  On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash

    5/16/22 9:21:33 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

    BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i

    8/5/21 5:00:00 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care